Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of Darolutamide on Cabazitaxel Systemic Exposure.
Buck SAJ, Guchelaar NAD, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, Oomen-de Hoop E, Westgeest HM, Hamberg P, Mathijssen-van Stein D, Lolkema MP, Koolen SLW, de Wit R, Mathijssen RHJ. Buck SAJ, et al. Among authors: guchelaar nad. Clin Pharmacokinet. 2022 Oct;61(10):1471-1473. doi: 10.1007/s40262-022-01159-6. Epub 2022 Jul 27. Clin Pharmacokinet. 2022. PMID: 35895277 No abstract available.
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.
van Kooten JP, Dietz MV, Guchelaar NAD, Brandt-Kerkhof ARM, Koolen SLW, Burger JWA, Mathijssen RHJ, Verhoef C, Aerts JGJV, Madsen EVE. van Kooten JP, et al. Among authors: guchelaar nad. BMJ Open. 2022 Jun 22;12(6):e062907. doi: 10.1136/bmjopen-2022-062907. BMJ Open. 2022. PMID: 35732399 Free PMC article. Clinical Trial.
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies.
Guchelaar NAD, Noordman BJ, Koolen SLW, Mostert B, Madsen EVE, Burger JWA, Brandt-Kerkhof ARM, Creemers GJ, de Hingh IHJT, Luyer M, Bins S, van Meerten E, Lagarde SM, Verhoef C, Wijnhoven BPL, Mathijssen RHJ. Guchelaar NAD, et al. Drugs. 2023 Feb;83(2):159-180. doi: 10.1007/s40265-022-01828-7. Epub 2023 Jan 12. Drugs. 2023. PMID: 36633826 Free PMC article. Review.
CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients.
van Eerden RAG, IJzerman NS, van Meekeren M, Oomen-de Hoop E, Guchelaar NAD, Visser AMW, Matic M, van Schaik RHN, de Bruijn P, Moes DAR, Jobse PA, Gelderblom H, Huitema ADR, Steeghs N, Mathijssen RHJ, Koolen SLW; Dutch Pharmacology Oncology Group. van Eerden RAG, et al. Among authors: guchelaar nad. Clin Pharmacokinet. 2023 Aug;62(8):1129-1139. doi: 10.1007/s40262-023-01260-4. Epub 2023 Jun 13. Clin Pharmacokinet. 2023. PMID: 37310647 Free PMC article.
Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.
van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW, Steeghs N. van der Kleij MBA, et al. Among authors: guchelaar nad. Clin Pharmacokinet. 2023 Oct;62(10):1333-1364. doi: 10.1007/s40262-023-01293-9. Epub 2023 Aug 16. Clin Pharmacokinet. 2023. PMID: 37584840 Free PMC article. Review.
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Ottevanger PB, Bloemendal HJ, Koolen SLW, Mathijssen RHJ, Boere IA, Hamberg P, Huitema ADR, Sonke GS, Opdam FL, Ter Heine R, van Erp NP. Overbeek JK, et al. Among authors: guchelaar nad. Eur J Cancer. 2023 Nov;194:113346. doi: 10.1016/j.ejca.2023.113346. Epub 2023 Sep 19. Eur J Cancer. 2023. PMID: 37806255 Free article. Clinical Trial.
COVID-19 Incidence and Disease Course Among Patients at an Allergy Department.
van der Aa LE, van Egmond IS, van der Sluijs M, den Otter AAS, Bosmans NHM, van Beek SE, Hartman A, Guchelaar NAD, van Daele PLA, van Maaren MS, van Hagen PM, Hermans MAW, Rombach SM. van der Aa LE, et al. Among authors: guchelaar nad. Ther Adv Allergy Rhinol. 2023 May 15;14:27534030231172391. doi: 10.1177/27534030231172391. eCollection 2023 Jan-Dec. Ther Adv Allergy Rhinol. 2023. PMID: 37207194 Free PMC article.
14 results